Sign inJoin waitlistJoin the waitlist

AM

Amal Melhem-Bertrandt

Internal Medicine

Credentials: ·

History

Internal Medicine
2006–2009
Medical School
2002–2006

Research

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Journal of Clinical Oncology · 2019 · 536 citations
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
Journal of Clinical Oncology · 2011 · First of 10 authors · Corresponding · 415 citations
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Journal of Clinical Oncology · 2020 · 302 citations

Gabriel Hortobagyi
6 papers
AG
Ana-Maria Gonzalez-Angulo
4 papers
Anil Sood
3 papers
EG
Elaina Gartner
3 papers
Funda Meric-Bernstam
3 papers
Mariana Mac Gregor
3 papers · 1 as a fellow
Olufunmilayo Olopade
3 papers
Suzanne Conzen
3 papers
Vicente Valero
3 papers
Daniel Petrylak
2 papers
EH
Elisabeth Heath
2 papers
FE
Francisco Esteva
2 papers